

Roche's Alzheimer's, breast cancer trials fail

Roche was ending a late-stage study of an experimental Alzheimer's drug after it failed to prove effective, underlining the difficulty of treating the memory-robbing disease. The Swiss drugmaker also said a breast cancer trial had failed to demonstrate the benefit of adding its new drug Kadcyla to treatment programmes, damaging its hopes of broadening sales in an commercial area it already dominates.
